Scarduelli C, Mattei A M, Brambilla G, Zavaglia C, Adelasco P, Cavioni V, Ferrari C
Gynecol Obstet Invest. 1985;19(2):92-6. doi: 10.1159/000299015.
The effects of two different doses (40 and 80 mg orally) of fenfluramine on serum prolactin (PRL) levels have been evaluated in healthy and hyperprolactinemic women and compared with those of the potent dopamine antagonist sulpiride (100 mg i.m.). The lower fenfluramine dose resulted in a significant PRL rise in healthy women (n = 16) but not in hyperprolactinemics (n = 14). A dose-response effect was shown between 40 and 80 mg in control subjects (n = 7); in 4 hyperprolactinemics the higher dose also failed to increase PRL levels. Sulpiride resulted in a much greater PRL response. Since fenfluramine at the low doses used does not seem to exert antidopaminergic action, it is suggested that the mild PRL stimulation observed be mediated by the known brain serotoninergic activation induced by the drug.
已在健康女性和高泌乳素血症女性中评估了两种不同剂量(口服40毫克和80毫克)的芬氟拉明对血清催乳素(PRL)水平的影响,并与强效多巴胺拮抗剂舒必利(100毫克,肌肉注射)的影响进行了比较。较低剂量的芬氟拉明使健康女性(n = 16)的PRL显著升高,但在高泌乳素血症患者(n = 14)中未出现这种情况。在对照组受试者(n = 7)中,40毫克至80毫克之间显示出剂量反应效应;在4名高泌乳素血症患者中,较高剂量也未能提高PRL水平。舒必利导致的PRL反应要大得多。由于所用低剂量的芬氟拉明似乎未发挥抗多巴胺能作用,因此有人提出,观察到的轻度PRL刺激是由该药物诱导的已知脑5-羟色胺能激活介导的。